These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 19116619)

  • 1. Regulatory watch: FDA PDUFA goals missed.
    Hay M
    Nat Rev Drug Discov; 2009 Jan; 8(1):10. PubMed ID: 19116619
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulatory watch: impact of PDUFA on regulatory decision-making.
    Hay M
    Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 4. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
    Kulynych J
    Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
    [No Abstract]   [Full Text] [Related]  

  • 6. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 8. Nuclear medicine wins decision in FDA PET case.
    Nichols D
    J Nucl Med; 1997 Dec; 38(12):23N. PubMed ID: 9430453
    [No Abstract]   [Full Text] [Related]  

  • 9. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 10. Staff resources speed FDA drug review: a critical analysis of the returns to resources in approval regulation.
    Carpenter D
    J Health Polit Policy Law; 2004 Jun; 29(3):431-42; discussion 443-50. PubMed ID: 15328873
    [No Abstract]   [Full Text] [Related]  

  • 11. Will politics sidetrack FDA reform?
    Gatty B
    Formulary; 1995 Aug; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract]   [Full Text] [Related]  

  • 12. Congress passes FDA reform act: nuclear medicine community stands to gain.
    Kotz D
    J Nucl Med; 1998 Jan; 39(1):15N-16N, 18N. PubMed ID: 9443722
    [No Abstract]   [Full Text] [Related]  

  • 13. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
    Burkhart CG
    J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
    [No Abstract]   [Full Text] [Related]  

  • 14. Patent watch: post-approval testing shielded from patent infringement.
    Harrison C
    Nat Rev Drug Discov; 2012 Sep; 11(9):666. PubMed ID: 23097768
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA is no place for politics.
    Nat Struct Mol Biol; 2006 May; 13(5):379. PubMed ID: 16738601
    [No Abstract]   [Full Text] [Related]  

  • 16. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 17. Reform bill to speed drugs to residents.
    Hawryluk M
    Provider; 1997 Nov; 23(11):37-8. PubMed ID: 10173669
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 19. Confronting the future of the FDA.
    Serafini MW
    Natl J (Wash); 1996 Dec; 28(50):2704-5. PubMed ID: 10163877
    [No Abstract]   [Full Text] [Related]  

  • 20. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.